Literature DB >> 21423247

Hypertension: meta-analyses: first-rank evidence or second-hand information?

Alberto Zanchetti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21423247     DOI: 10.1038/nrcardio.2011.39

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials.

Authors:  Franz H Messerli; Harikrishna Makani; Alexandre Benjo; Jorge Romero; Carlos Alviar; Sripal Bangalore
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis.

Authors:  Giuseppe Mancia; Gianfranco Parati
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

3.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

4.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

Authors:  L Hansson; L H Lindholm; T Ekbom; B Dahlöf; J Lanke; B Scherstén; P O Wester; T Hedner; U de Faire
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

5.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

6.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

7.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

8.  Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.

Authors:  Alberto Zanchetti; Gaetano Crepaldi; M Gene Bond; Giuseppe Gallus; Fabrizio Veglia; Giuseppe Mancia; Alessandro Ventura; Giovannella Baggio; Lorena Sampieri; Paolo Rubba; Giovanni Sperti; Alberto Magni
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

9.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

Authors: 
Journal:  BMJ       Date:  1992-02-15
  9 in total
  1 in total

Review 1.  Quality of Meta-Analyses for Randomized Trials in the Field of Hypertension: an Updated and Improved Systematic Review.

Authors:  George C Roush; Fiorella Perez; Ramy Abdelfattah; Andrew Prindle; Elie Jean; Tanveer Singh; John B Kostis; William J Kostis; William J Elliott; Jesse A Berlin
Journal:  Curr Hypertens Rep       Date:  2017-09       Impact factor: 5.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.